12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Company News  |  Other News

to-BBB ophthalmic, drug delivery news

to-BBB said it received €1.3 million ($1.6 million) in funding from the EU's Seventh Framework Program (FP7) as part of a consortium focused on the preclinical development of treatments for inherited retinal degenerative diseases. The three-year DRUGSFORD consortium received €5 million ($6.3...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >